New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public.SO WHAT: If you purchased agilon health securities you may be entitled to compensation without payment of any out of pocket fees or costs through a c ...

Key Takeaways Acadia's Q3 adjusted EPS of 72 cents beat estimates but dropped 20.9% year over year.Revenues grew 4.4% to $851.6M, driven by higher admissions and patient days despite cost pressure.Guidance was cut, with 2025 EPS now seen at $2.35-$2.45 and revenue at $3.28-$3.30B.Acadia Healthcare Company, Inc. (ACHC) reported adjusted third-quarter earnings of 72 cents per share, which beat the Zacks Consensus Estimate by 7.5%. However, the bottom line declined 20.9% year over year. Total revenues increase ...

Core Insights - The healthcare industry is experiencing potential disruption from artificial intelligence (AI) technology, presenting investment opportunities for the Fidelity Disruptive Medicine ETF (FMED) [1] Investment Focus - FMED targets companies that are positioned to disrupt the healthcare sector with innovative solutions, including Boston Scientific Corp, Alynlam Pharma, and Argenx, which may not be as recognizable as larger firms like Eli Lilly or UnitedHealth [2] - The ETF is actively managed, allowing portfolio managers to adjust holdings based on market conditions, with exposure to areas such as robotic surgery, gene therapy, genomics, rare diseases, medical devices, immunotherapy, and technology-based healthcare platforms [3] AI Integration in Healthcare - FMED includes companies utilizing AI to provide innovative healthcare solutions, with rising capital investment in the sector supporting the investment case for such funds [4] - A report from the World Economic Forum highlights ongoing challenges in healthcare, noting that 4.5 billion people lack access to essential services and forecasting a shortage of 11 million healthcare workers by 2030, creating opportunities for AI-driven delivery services [5] - AI digital health solutions are expected to enhance efficiency, reduce costs, and improve health outcomes globally, emphasizing the need for further investment in AI [6]

REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financi ...

Group 1 - The core message emphasizes the commitment of various health and science organizations in Guangxi to implement the spirit of the 20th Central Committee's Fourth Plenary Session, focusing on high-quality development in the health and technology sectors to support the "14th Five-Year Plan" and lay a solid foundation for the "15th Five-Year Plan" [1][2][3] - The Guangxi Health Commission aims to enhance the health system, improve medical services, and promote a healthier population by implementing a health-first development strategy and strengthening the "three medical" collaborative development and governance mechanisms [1] - The Guangxi Academy of Sciences plans to align its research with national strategies, focusing on key areas such as artificial intelligence and critical metals, to foster technological self-reliance and innovation [2] Group 2 - The Guangxi Traditional Chinese Medicine Bureau is integrating the spirit of the plenary session into its development plans, aiming to enhance the international influence of Guangxi's traditional medicine through projects and collaborations with ASEAN countries [2] - The Guangxi Center for Disease Control is committed to improving its disease control capabilities and applying artificial intelligence in public health, while also focusing on building a "National Gate Disease Control" joint system [2][3] - The Guangxi Drug Administration is prioritizing the implementation of a comprehensive drug and medical device regulatory reform plan to ensure high-quality development in the pharmaceutical industry, emphasizing safety and accountability throughout the drug supply chain [3]

Key Takeaways 3D Systems reported a Q3 non-GAAP loss of 8 cents per share, beating consensus estimates. Revenue fell 19.2% year over year to $91.2 million, hurt by lower product sales and divestitures. The company projects 8-10% revenue growth in Q4 on higher printer sales and healthcare demand. 3D Systems (DDD) reported a third-quarter 2025 non-GAAP loss of 8 cents per share that beat the Zacks Consensus Estimate by 11.11%. The figure was narrower than the reported loss of 9 cents per share in the year-ago ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

DuPont De Nemours (NYSE:DD) Q3 2025 Earnings Call November 06, 2025 08:00 AM ET Company ParticipantsAnn Giancristoforo - Head of Investor RelationsLori Koch - CEOAntonella Franzen - CFOConference Call ParticipantsMatthew DeYoe - Research AnalystScott Davis - AnalystJosh Spector - Equity Research AnalystRachael Lee - AnalystMichael Sison - AnalystJohn Patrick - AnalystJohn Roberts - AnalystJeffrey Sprague - Senior Equity Research AnalystChris Parkinson - AnalystTurner Hinrichs - Equity Research AnalystArun V ...

With a market cap of $218.8 billion, Abbott Laboratories (ABT) is a global healthcare leader with a diversified portfolio spanning medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. The North Chicago, Illinois-based company is best known for innovations like its FreeStyle Libre glucose monitoring system. Abbott plays a major role in chronic disease management, lab testing technologies, and specialized nutrition with brands such as Ensure, Pedialyte, and Similac. Over the past ye ...